All In Biotech

Drug Trial Radar · NCT05253651

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 325 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

325

Actual

Start

Oct 24, 2022

Primary completion

Dec 31, 2027

Study completion Jul 3, 2030

Sponsor

Sponsor type
Industry
First posted
Feb 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.

Conditions

  • Colorectal Neoplasms

Interventions

  • tucatinibDrug

    300mg given by mouth (orally) twice daily

  • trastuzumabDrug

    8mg/kg loading dose will be given into the vein (IV; intravenously) on Cycle 1 day 1, followed by 6mg/kg given by IV every 3 weeks thereafter.

  • bevacizumabDrug

    5mg/kg given by IV every 2 weeks

  • cetuximabDrug

    400mg/m2 loading dose will be given by IV on Cycle 1 day 1, followed by 250mg/m2 given by IV weekly

  • oxaliplatinDrug

    85mg/m2 given by IV every 2 weeks. Component of mFOLFOX6.

  • leucovorinDrug

    400mg/ m2 given by IV every 2 weeks. Component of mFOLFOX6.

  • levoleucovorinDrug

    200mg/ m2 given by IV every 2 weeks. May be given in place of leucovorin. Component of mFOLFOX6.

  • fluorouracilDrug

    400mg/m2 given by IV bolus then 2400mg/m2 given by continuous IV infusion (over 46-48 hours) every 2 weeks. Component of mFOLFOX6.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR)Time frame: Up to approximately 3 years

Locations

319 sites in 24 countries. Site status is shown where the registry gives one.

  • Palo Verde Hematology Oncology

    Glendale, Arizona

  • Mayo Clinic Building - Phoenix

    Phoenix, Arizona

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • Mayo Clinic

    Scottsdale, Arizona

  • Los Angeles Cancer Network - Anaheim

    Anaheim, California

  • Kaiser Permanente Anaheim Kraemer Medical Offices

    Anaheim, California

  • Kaiser Permanente Baldwin Park Medical Center

    Baldwin Park, California

  • Kaiser Permanente Bellflower Medical Offices

    Bellflower, California

  • Kaiser Permanente Fontana Medical Center

    Fontana, California

  • Los Angeles Cancer Network - Fountain Vally

    Fountain Valley, California

  • Los Angeles Cancer Network - Corporate Office

    Glendale, California

  • Los Angeles Hematology Oncology Medical Group

    Glendale, California

  • Los Angeles Hematology Oncology Medical Group

    Glendale, California

  • Kaiser Permanente South Bay Medical center

    Harbor City, California

  • Kaiser Permanente Alton/Sand Canyon Medical Offices

    Irvine, California

  • Los Angeles Hematology Oncology Medical Group

    Los Angeles, California

  • USC Norris Koreatown - Medical Oncology

    Los Angeles, California

  • Kaiser Permanente Los Angeles Medical Offices

    Los Angeles, California

  • Keck Hospital of USC

    Los Angeles, California

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • Kaiser Permanente West Los Angeles Medical Center

    Los Angeles, California

  • USC Norris Oncology/Hematology - Newport Beach

    Newport Beach, California

  • Kaiser Permanente Ontario Medical Center

    Ontario, California

  • Kaiser Permanente Panorama City Medical Center

    Panorama City, California

  • Keck Medical Center of USC Pasadena

    Pasadena, California

  • Los Angeles Hematology Oncology Medical Group

    Pasadena, California

  • Kaiser Permanente Riverside Medical Center

    Riverside, California

  • Kaiser Permanente San Diego Mission Road (Regulatory and Lab Supplies)

    San Diego, California

  • Kaiser Permanente Zion Medical Center

    San Diego, California

  • Kaiser Permanente San Marcos Medical Offices

    San Marcos, California

  • Los Angeles Hematology Oncology Medical Group

    Van Nuys, California

  • Kaiser Permanente Woodland Hills Medical Center

    Woodland Hills, California

  • Rocky Mountain Cancer Centers, LLP

    Aurora, Colorado

  • Rocky Mountain Cancer Centers, LLP

    Boulder, Colorado

  • Rocky Mountain Cancer Centers, LLP

    Colorado Springs, Colorado

  • Rocky Mountain Cancer Centers, LLP

    Denver, Colorado

  • Rocky Mountain Cancer Centers, LLP

    Denver, Colorado

  • Rocky Mountain Cancer Centers, LLP

    Lakewood, Colorado

  • Rocky Mountain Cancer Centers, LLP

    Littleton, Colorado

Showing 40 of 319 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.